Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
0.7400
-0.0340 (-4.39%)
At close: Oct 23, 2026, 4:00 PM EDT
0.7420
+0.0020 (0.27%)
After-hours: Oct 23, 2026, 4:54 PM EDT
Creative Medical Technology Holdings Employees
Creative Medical Technology Holdings had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Creative Medical Technology Holdings the 42,329th largest employer in the world and 6,654th in the United States.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$750
Profits / Employee
-$1,510,165
Market Cap
4.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| AIM ImmunoTech | 21 |
| NeuroSense Therapeutics | 17 |
| Cardio Diagnostics Holdings | 17 |
| Azitra | 13 |
| NuCana | 12 |
| Lexaria Bioscience | 7 |
| Traws Pharma | 7 |
CELZ News
- 4 days ago - Creative Medical provides additional clinical, laboratory findings for Ultrasome - TheFly
- 4 days ago - Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study - GlobeNewsWire
- 5 weeks ago - Creative Medical files new U.S. provisional patent application for Ultrasome - TheFly
- 5 weeks ago - Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing - GlobeNewsWire
- 2 months ago - Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’ - TheFly
- 2 months ago - Creative Medical completes enrollment in ADAPT clinical trial - TheFly
- 2 months ago - Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning - GlobeNewsWire
- 2 months ago - Creative Medical receives notice of allowance for new U.S. patent - TheFly